Biocytogen Sets 21 May 2026 for 2025 AGM; Agenda Covers Profit Distribution, Capital Increase and Credit Facilities

Bulletin Express04-23

Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (“Biocytogen”) will convene its 2025 Annual General Meeting (AGM) at 14:00 on 21 May 2026. Shareholders may participate in person at 12 Baoshen South Street, Daxing Bio-Medicine Industry Park, Beijing, or online via the eVoting Portal (https://evoting.vistra.com).

Key ordinary resolutions 1. Board work report for 2025. 2. Re-appointment of KPMG as auditor for 2026 with board-delegated authority to set remuneration. 3. Director allowances for 2026. 4. Profit distribution plan for 2025. 5. Confirmation of 2025 related-party transactions and estimated transactions for 2026.

Key special resolutions 6. Application for comprehensive credit facilities and provision of guarantees for the company and its subsidiaries. 7. Increase in registered capital and corresponding amendments to the Articles of Association.

Reports to be received (no vote required) • Senior management remuneration plan for 2026. • Independent non-executive directors’ 2025 work report.

Shareholder logistics • Register of H shareholders closes 18–21 May 2026 (both days inclusive). • Share transfers must reach Tricor Investor Services Limited by 16:30 on 15 May 2026 to qualify for voting rights. • Proxy forms (physical or electronic) must be submitted no later than 14:00 on 20 May 2026. • All resolutions will be decided by poll, with results published on the HKEX and company websites.

Biocytogen’s board is chaired by Shen Yuelei, who also serves as CEO and executive director. The notice was released on 23 April 2026.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1149536872?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-04-23 21:03","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1149536872","market":"us","top_or_hot":-1,"title":"Biocytogen Sets 21 May 2026 for 2025 AGM; Agenda Covers Profit Distribution, Capital Increase and Credit Facilities","media":"Bulletin Express","content":"<p>Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (“Biocytogen”) will convene its 2025 Annual General Meeting (AGM) at 14:00 on 21 May 2026. Shareholders may participate in person at 12 Baoshen South Street, Daxing Bio-Medicine Industry Park, Beijing, or online via the eVoting Portal (https://evoting.vistra.com).</p>\n<p>Key ordinary resolutions  \n1. Board work report for 2025.  \n2. Re-appointment of KPMG as auditor for 2026 with board-delegated authority to set remuneration.  \n3. Director allowances for 2026.  \n4. Profit distribution plan for 2025.  \n5. Confirmation of 2025 related-party transactions and estimated transactions for 2026.</p>\n<p>Key special resolutions  \n6. Application for comprehensive credit facilities and provision of guarantees for the company and its subsidiaries.  \n7. Increase in registered capital and corresponding amendments to the Articles of Association.</p>\n<p>Reports to be received (no vote required)  \n• Senior management remuneration plan for 2026.  \n• Independent non-executive directors’ 2025 work report.</p>\n<p>Shareholder logistics  \n• Register of H shareholders closes 18–21 May 2026 (both days inclusive).  \n• Share transfers must reach Tricor Investor Services Limited by 16:30 on 15 May 2026 to qualify for voting rights.  \n• Proxy forms (physical or electronic) must be submitted no later than 14:00 on 20 May 2026.  \n• All resolutions will be decided by poll, with results published on the HKEX and company websites.</p>\n<p>Biocytogen’s board is chaired by Shen Yuelei, who also serves as CEO and executive director. The notice was released on 23 April 2026.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Biocytogen Sets 21 May 2026 for 2025 AGM; Agenda Covers Profit Distribution, Capital Increase and Credit Facilities</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBiocytogen Sets 21 May 2026 for 2025 AGM; Agenda Covers Profit Distribution, Capital Increase and Credit Facilities\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1053168898\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Bulletin Express </p>\n<p class=\"h-time\">2026-04-23 21:03</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (“Biocytogen”) will convene its 2025 Annual General Meeting (AGM) at 14:00 on 21 May 2026. Shareholders may participate in person at 12 Baoshen South Street, Daxing Bio-Medicine Industry Park, Beijing, or online via the eVoting Portal (https://evoting.vistra.com).</p>\n<p>Key ordinary resolutions  \n1. Board work report for 2025.  \n2. Re-appointment of KPMG as auditor for 2026 with board-delegated authority to set remuneration.  \n3. Director allowances for 2026.  \n4. Profit distribution plan for 2025.  \n5. Confirmation of 2025 related-party transactions and estimated transactions for 2026.</p>\n<p>Key special resolutions  \n6. Application for comprehensive credit facilities and provision of guarantees for the company and its subsidiaries.  \n7. Increase in registered capital and corresponding amendments to the Articles of Association.</p>\n<p>Reports to be received (no vote required)  \n• Senior management remuneration plan for 2026.  \n• Independent non-executive directors’ 2025 work report.</p>\n<p>Shareholder logistics  \n• Register of H shareholders closes 18–21 May 2026 (both days inclusive).  \n• Share transfers must reach Tricor Investor Services Limited by 16:30 on 15 May 2026 to qualify for voting rights.  \n• Proxy forms (physical or electronic) must be submitted no later than 14:00 on 20 May 2026.  \n• All resolutions will be decided by poll, with results published on the HKEX and company websites.</p>\n<p>Biocytogen’s board is chaired by Shen Yuelei, who also serves as CEO and executive director. The notice was released on 23 April 2026.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"02315","symbol_name":"百奥赛图-B","start_time":0,"source_url":"","article_id":"1149536872","we_media_id":"1053168898","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1149536872","pubTimestamp":1776949389,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Bulletin Express","introduction":"Full Coverage of HK & US Stock Announcements","home_visible":1,"id":"1053168898","head_image":"https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e"},"summary":"Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (“Biocytogen”) will convene its 2025 Annual General Meeting (AGM) at 14:00 on 21 May 2026. Shareholders may participate in person at 12 Baoshen South...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"02315":"百奥赛图-B"},"translate_title":"Biocytogen定于2026年5月21日召开2025年年度股东大会；议程涵盖利润分配、增资和信贷便利","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"02315":1},"content_text":"Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (“Biocytogen”) will convene its 2025 Annual General Meeting (AGM) at 14:00 on 21 May 2026. Shareholders may participate in person at 12 Baoshen South Street, Daxing Bio-Medicine Industry Park, Beijing, or online via the eVoting Portal (https://evoting.vistra.com).\nKey ordinary resolutions  \n1. Board work report for 2025.  \n2. Re-appointment of KPMG as auditor for 2026 with board-delegated authority to set remuneration.  \n3. Director allowances for 2026.  \n4. Profit distribution plan for 2025.  \n5. Confirmation of 2025 related-party transactions and estimated transactions for 2026.\nKey special resolutions  \n6. Application for comprehensive credit facilities and provision of guarantees for the company and its subsidiaries.  \n7. Increase in registered capital and corresponding amendments to the Articles of Association.\nReports to be received (no vote required)  \n• Senior management remuneration plan for 2026.  \n• Independent non-executive directors’ 2025 work report.\nShareholder logistics  \n• Register of H shareholders closes 18–21 May 2026 (both days inclusive).  \n• Share transfers must reach Tricor Investor Services Limited by 16:30 on 15 May 2026 to qualify for voting rights.  \n• Proxy forms (physical or electronic) must be submitted no later than 14:00 on 20 May 2026.  \n• All resolutions will be decided by poll, with results published on the HKEX and company websites.\nBiocytogen’s board is chaired by Shen Yuelei, who also serves as CEO and executive director. The notice was released on 23 April 2026.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"SGX","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.42.2","shortVersion":"4.42.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1149536872","isCrawlerRequest":true}